Elucidation of cell culture impacts on hydroxylysine levels in monoclonal antibodies using high‐throughput analytical quantification and media components
Biotechnology Progress · 2025
DOI: 10.1002/btpr.70068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Progress, 2025. Verfasst von Roli Kargupta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Process Research and Development, Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Lysine, Culture Media, Cell Culture Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Hydroxylysine (Hyl) is a post‐translational hydroxyl modification of lysine that is not commonly observed at very high levels and thus is not usually considered a product quality attribute (PQA). Post‐translation modifications (PTMs) are considered potential PQAs when elevated levels are observed – requiring monitoring and investigation. In a recent monoclonal antibody expression using Media A, Hyl levels were observed at ~20%–35%. At such elevated percentage levels, Hyl was considered a PQA – triggering a root‐cause investigation in the upstream activities like cell culture conditions and media components. Initial detection of the Hyl modification originated from non‐quantitative, intact mass analysis with confirmation of site‐location determined by peptide mapping. Through the root‐cause investigation, it was determined that levels of Hyl were underestimated by ~10‐fold using tryptic peptide mapping analysis without inclusion of miscleaved peptides. The analytical procedure was revised from trypsin‐digestion to IdeS‐digestion, a reduced mass analysis, to accurately and rapidly quantify Hyl levels of investigational samples. Proprietary Media B was utilized to reduce the Hyl level by 2‐fold to ~10%–15%. Further investigation into the media and feed components determined that increasing concentration of Fe(III) content decreased Hyl levels. Supplementation of Fe(III) served as a robust mitigation strategy of Hyl reduction in upstream process. Media B was used to scale up to a 500 L bioreactor while maintaining the lower Hyl level. The analytical and cell culture methods developed in this study can be leveraged to detect and tune Hyl levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck & Co., Inc., Process Research and Development, Rahway, New Jersey, USA.
- Merck & Co., Inc., Analytical Research and Development, Rahway, New Jersey, USA.
ORCID-Profile: Shannon Rivera
Zitieren
APA
Kargupta, R., Rivera, S., Kochert, B., Devenney, K., Donelly, D., Atieh, T., Li, F., Pan, J., Patel, D., Tayi, V., Chauhan, G., Chmielowski, R., & Abbondanzo, S. J. (2025). Elucidation of cell culture impacts on hydroxylysine levels in monoclonal antibodies using high‐throughput analytical quantification and media components. Biotechnology Progress. https://doi.org/10.1002/btpr.70068
Vancouver
Kargupta R, Rivera S, Kochert B, Devenney K, Donelly D, Atieh T, et al. Elucidation of cell culture impacts on hydroxylysine levels in monoclonal antibodies using high‐throughput analytical quantification and media components. Biotechnology Progress. 2025. doi:10.1002/btpr.70068
BibTeX
@article{Kargupta2025,
author = {Kargupta, Roli and Rivera, Shannon and Kochert, Brent and Devenney, Kyle and Donelly, Daniel and Atieh, Tariq and Li, Fang and Pan, Jessica and Patel, Daya and Tayi, Venkata and Chauhan, Gaurav and Chmielowski, Rebecca and Abbondanzo, Susan J},
title = {Elucidation of cell culture impacts on hydroxylysine levels in monoclonal antibodies using high‐throughput analytical quantification and media components},
journal = {Biotechnology Progress},
year = {2025},
doi = {10.1002/btpr.70068}
}
EUVIMED